CCC publication: Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study

Citation: Journal of Clinical Oncology. 2021, 39(15)

Author: Palmieri C.; Linden H.M.; Birrell S.; Lim E.; Schwartzberg L.S.; Rugo H.S.; Cobb P.W.; Jain K.; Vogel C.L.; O'Shaughnessy J.; Johnston S.R.D.; Getzenberg R.H.; Barnette K.G.; Steiner M.S.; Brufsky A.; Overmoyer B